Mitochondrial nutrition as a strategy for neuroprotection in Parkinson's disease - Research focus in the department of alternative medicine and experimental therapeutics at Hokuriku university

Evidence-based Complementary and Alternative Medicine

Volumn 4, Issue 2, 2007, Pages 263-265

  Mitsumoto, Yasuhide ^a  

^a HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

UBIDECARENONE;

ALTERNATIVE MEDICINE; APOPTOSIS; CELL DEATH; CELL FUNCTION; DIET THERAPY; EXERCISE; HUMAN; MENTAL HEALTH; MITOCHONDRION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 52449088325     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nel115     Document Type: Review

References (27)

1. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Ann Rev Neurosci 1999;22:123-44.
2. Agid Y. Parkinson's disease: pathophisiology. Lancet 1991;337:1321-4.
3. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53.
4. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60:1234-40.
5. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurol 2006;66:664-71.
6. Olanow CW, Schapira AHV, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5:1013-20.
7. Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, et al. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 2000;12:3033-43.
8. Andringa G, Eshuis S, Perentes E. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis 2003;14:205-17.
9. Sawa A, Khan AA, Hester LD, Snyder SH. Glyderaldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuronal cell death. Proc Natl Acad Sci USA 1997;94:11669-74.
10. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996;278:447-54.
11. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
12. Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res 2005;51:265-74.
13. Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, et al. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur J Neurosci 2006;23:1077-81.
14. Ohashi S, Mori A, Kurihara N, Mitsumoto Y, Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci Lett 2006;401:183-7.
15. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
16. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-23.
17. Mizuno Y, Yoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsubayashi S, et al. Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 1998;44:(Suppl 1):S99-109.
18. Murphy AN, Fiskum G, Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab 1999;19:231-45.
19. Nakai M, Mori A, Watanabe A, Mitsumoto Y. 1-Methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (DJm) in rat striatum. Exp Neurol 2003;179:103-10.
20. Shults CW. Mitochondrial dysfunction and possible treatments in Parkinson's disease - a review. Mitochondrion 2004;4:641-8.
21. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997;42:261-4.
22. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
23. Moon Y, Lee KH, Park J-H, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 2005;93:1199-208.
24. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandeya S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis 2005;18:618-27.
25. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998;783:109-14.
26. Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M, et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinol 2003;144:2757-60.
27. Andrews ZB, Horvath B, Barnstable CJ, Elseworth J, Yang L, Beal MF, et al. Uncoupling Protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's Disease. J Neurosci 2005;25:184-91.